Suchen
Mainz Biomed NV
MYNZZur Watchlist hinzufügen
0.844USD
0.0000.00%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
35.06MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Mainz Biomed NV Unternehmen
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Mainz Biomed NV Informationen
BörsenkürzelMYNZ
Name des UnternehmensMainz Biomed NV
IPO-datumNov 04, 2021
CEOBaechler (Guido)
Anzahl der mitarbeiter19
WertpapierartOrdinary Share
GeschäftsjahresendeNov 04
AddresseSirius Gutenberg Park
StadtMAINZ
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl55129
Telefon496131265140
Websitehttps://www.mainzbiomed.com/
BörsenkürzelMYNZ
IPO-datumNov 04, 2021
CEOBaechler (Guido)
Führungskräfte von Mainz Biomed NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
64.50K
+96.59%
Mr. Hans Hekland
Mr. Hans Hekland
Non-Executive Independent Director
Non-Executive Independent Director
56.00K
+68.27%
Mr. Gregory J. (Greg) Tibbitts
Mr. Gregory J. (Greg) Tibbitts
Non-Executive Independent Director
Non-Executive Independent Director
55.88K
+17.90%
Mr. Guido Baechler
Mr. Guido Baechler
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36K
-9410.50%
Dr. Chris von Toerne
Dr. Chris von Toerne
Chief Operating Officer
Chief Operating Officer
2.50K
+93.24%
Mr. William Caragol
Mr. William Caragol
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
64.50K
+96.59%
Mr. Hans Hekland
Mr. Hans Hekland
Non-Executive Independent Director
Non-Executive Independent Director
56.00K
+68.27%
Mr. Gregory J. (Greg) Tibbitts
Mr. Gregory J. (Greg) Tibbitts
Non-Executive Independent Director
Non-Executive Independent Director
55.88K
+17.90%
Mr. Guido Baechler
Mr. Guido Baechler
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36K
-9410.50%
Dr. Chris von Toerne
Dr. Chris von Toerne
Chief Operating Officer
Chief Operating Officer
2.50K
+93.24%
Mr. William Caragol
Mr. William Caragol
Chief Financial Officer
Chief Financial Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Mainz Biomed NV?
Die fünf größten Anteilseigner von Mainz Biomed NV sind: Dr. Heiner Dreismann, Ph.D.
Wie viele Institutionen halten Anteile an Mainz Biomed NV (MYNZ)?
Mit Stand vom 2026Q1 halten 33 Institutionen Anteile an Mainz Biomed NV, mit einem Gesamtmarktwert von etwa 1.23M, was 9.84% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 663009.00 gestiegen.